

CURRICULUM VITAE

NAME Tommaso Zanocco-Marani

ADDRESS

Dipartimento di Scienze della Vita
Università degli Studi di Modena
Via Campi, 287
41100, Modena
Tel. +390592055721

E-MAIL zanocco@unimore.it

BIRTH: 29, OTTOBRE, 1971

BIRTH PLACE: FIRENZE, ITALIA

FOREIGN LANGUAGES: INGLESE, FRANCESE, TEDESCO

STUDIES

1986 -1990 Liceo Classico Sperimentale "L.A. Muratori",
Modena

1991 - 1995 Corso di Laurea in Scienze Biologiche, Università di Modena.

28, Novembre, 1995 Degree in Biology: "Ruolo del Protooncogene c-Fes durante il Differenziamento Macrofagico delle cellule HL-60".

RESEARCH EXPERIENCE:

Dicembre 2005- Ricercatore Bio13 Facoltà di Medicina, Università di Modena e Reggio Emilia

2004-2005 Borsa triennale AIRC "Mario e Valeria Rindi" per la ricerca sul cancro.

2003-2004 Assegno di Ricerca presso l'Università di Modena e Reggio Emilia, Dipartimento di Scienze Biomediche, Sezione di Chimica Biologica.

1999 - 2003 Ph.D. in BIOTECHNOLOGY and Experimental Medicine, University of Modena and Reggio Emilia Dottorato in Biotecnologie e Medicina Sperimentale presso l'Università di Modena e Reggio Emilia. Thesis: "Requirement of the Coiled Coil domains of p92c-Fes for Nuclear Localization in Myeloid Cells upon Induction of Differentiation".

1997 - 1999 Postdoctoral Fellow, Kimmel Cancer Institute, Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA.

1993 - 1997 Internato in Biologia Molecolare , Dipartimento di Scienze Biomediche, Università di Modena. "Ruolo del protooncogene c- Fes durante il differenziamento macrofagico delle cellule HL-60".

Luglio/Agosto 1993 Summer student, Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, PA

PUBLICATIONS

1. Functional Interplay Between TTP/ZFP36 and HuR/ELAVL1 in Cancer: A Post-Transcriptional Regulatory Network. Lotti R., Selmi T., Grande A., **Zanocco-Marani T.** Frontiers in Oncology. 2026. In press.

2. Treatment of pemphigus and other neglected skin conditions with PC111, a human anti-Fas Ligand monoclonal antibody: a potential disease modifier. Lotti R, Amato A, Bennett B, **Zanocco-Marani T**, Marconi A, Pincelli C. *J Dermatolog Treat.* 2025 Dec;36(1):2526075.
3. Supra-Physiological Levels of Magnesium Counteract the Inhibitory Effect of Zoledronate on RANKL-Dependent Osteoclastogenesis. Caselli L, De Pasquale L, Palumbo R, Ricchiuto S, Montanari M, Rontautoli S, Ottani A, Norfo R, **Zanocco-Marani T**, Grande A. *Biology (Basel).* 2025 May 11;14(5):533.
4. The Capacity of Magnesium to Induce Osteoclast Differentiation Is Greatly Enhanced by the Presence of Zoledronate. Ricchiuto S, Palumbo R, Lami F, Gavioli F, Caselli L, Montanari M, Zappavigna V, Anesi A, **Zanocco-Marani T**, Grande A. *Biology (Basel).* 2023 Sep 29;12(10):1297. doi: 10.3390/biology12101297.
5. BS148 Reduces the Aggressiveness of Metastatic Melanoma via Sigma-2 Receptor Targeting. Sorbi, C.; Belluti, S.; Atene, C.G.; Marocchi, F.; Linciano, P.; Roy, N.; Paradiso, E.; Casarini, L.; Ronsisvalle, S.; **Zanocco-Marani, T.**; et al. *Int. J. Mol. Sci.* 2023, 24, 9684.
6. A Novel In Vivo Active Pemphigus Model Targeting Desmoglein1 and Desmoglein3: A Tool Representing All Pemphigus Variants. Lotti R, Atene CG, Zanfi ED, Bertesi M, Pincelli C, **Zanocco-Marani T.** *Biology (Basel).* 2023 May 11;12(5):702.
7. In Vitro, Ex Vivo, and In Vivo Models for the Study of Pemphigus. Lotti R, Atene CG, Zanfi ED, Bertesi M, **Zanocco-Marani T.** *Int J Mol Sci.* 2022 Jun 24;23(13):7044.
8. Magnesium favors the capacity of vitamin D3 to induce the monocyte differentiation of U937 cells. Parenti S, Sandoni L, Montanari M, **Zanocco-Marani T**, Anesi A, Iotti S, Manfredini R, Frassinetti C, Davalli P, Grande A. *Magnes Res.* 2021 Aug 1;34(3):114-129.
9. Promoter Methylation Leads to Decreased ZFP36 Expression and Deregulated NLRP3 Inflammasome Activation in Psoriatic Fibroblasts. Bertesi M, Fantini S, Alecci C, Lotti R, Martello A, Parenti S, Carretta C, Marconi A, Grande A, Pincelli C, **Zanocco-Marani T.** *Front Med (Lausanne).* 2021 Jan 22;7:579383.
10. Wnt/CTNNB1 Signal Transduction Pathway Inhibits the Expression of ZFP36 in Squamous Cell Carcinoma, by Inducing Transcriptional Repressors SNAI1, SLUG and TWIST. Zanfi ED, Fantini S, Lotti R, Bertesi M, Marconi A, Grande A, Manfredini R, Pincelli C, **Zanocco-Marani T.** *Int J Mol Sci.* 2020 Aug 8;21(16):5692.
11. Cadherins down-regulation: towards a better understanding of their relevance in colorectal cancer. Losi L, **Zanocco-Marani T**, Grande A. *Histol Histopathol.* 2020 Dec;35(12):1391-1402.
12. Depletion of Trichoplein (TpMs) Causes Chromosome Mis-Segregation, DNA Damage and Chromosome Instability in Cancer Cells. Lauriola A, Martello A, Fantini S, Marverti G, **Zanocco-Marani T**, Davalli P, Guardavaccaro D, Mai S, Caporali A, D'Arca D. *Cancers (Basel).* 2020 Apr 17;12(4):993.
13. Development of a Desmocollin-3 Active Mouse Model Recapitulating Human Atypical Pemphigus. Lotti R, Atene CG, Marconi A, Di Rocco G, Reggiani Bonetti L, **Zanocco Marani T**, Pincelli C. *Front Immunol.* 2019 Jun 19;10:1387.
14. Physiological expression of miR-130a during differentiation of CD34+ human hematopoietic stem cells results in the inhibition of monocyte differentiation. Mammoli F, Parenti S, Lomiento M, Gemelli C, Atene CG, Grande A, Corradini R, Manicardi A, Fantini S, **Zanocco-Marani T**, Ferrari S. *Exp Cell Res.* 2019 Sep 1;382(1):111445.
15. Loss of expression of μ -protocadherin and protocadherin-24 in sporadic and hereditary nonpolyposis colorectal cancers. Losi L, Lancellotti C, Parenti S, Scurani L, **Zanocco-Marani T**, Buffoli F, Grassia R, Ferrari S, Grande A. *Hum Pathol.* 2019 Feb;84:299-308.

16. KLF4 Mediates the Effect of 5-ASA on the β -Catenin Pathway in Colon Cancer Cells. Parenti S, Montorsi L, Fantini S, Mammoli F, Gemelli C, Atene CG, Losi L, Frassinetti C, Calabretta B, Tagliafico E, Ferrari S, **Zanocco-Marani T**, Grande A. *Cancer Prev Res (Phila)*. 2018 Aug;11(8):503-510.
17. Loss of zfp36 expression in colorectal cancer correlates to wnt/ β -catenin activity and enhances epithelial-to-mesenchymal transition through upregulation of zeb1, sox9 and macc1. Montorsi L, Guizzetti F, Alecci C, Caporali A, Martello A, Giacinto Atene C, Parenti S, Pizzini S, Zanollevo P, Bortoluzzi S, Ferrari S, Grande A, **Zanocco-Marani T**. *Oncotarget*. 2016 Jul 24.
18. Expression of μ -protocadherin is negatively regulated by the activation of the β - catenin signaling pathway in normal and cancer colorectal enterocytes. Montorsi L, Parenti S, Losi L, Ferrarini F, Gemelli C, Rossi A, Manco G, Ferrari S, Calabretta B, Tagliafico E, **Zanocco-Marani T**, Grande A. *Cell Death Dis*. 2016 Jun 16;7
19. ZFP36 stabilizes RIP1 via degradation of XIAP and cIAP2 thereby promoting Ripoptosome assembly. Selmi T, Alecci C, dell'Aquila M, Montorsi L, Martello A, Volpi N, Grande A, Parenti S, Ferrari S, Salomoni P and **Zanocco-Marani T**. *BMC Cancer*. 2015 May 6;15:357.
20. MafB is a downstream target of the IL-10/STAT3 signaling pathway, involved in the regulation of macrophage de-activation. Gemelli C, **Zanocco Marani T**, Bicciato S, Mazza EM, Boraschi D, Salsi V, Zappavigna V, Parenti S, Selmi T, Tagliafico E, Ferrari S, Grande A. *Biochim Biophys Acta*. 2014 May;1843(5):955-64.
21. Characterization of Clinical and Molecular Features Related to the Downregulated Expression of μ -Protocadherin in Colorectal Cancer. Losi L, Benhattar J, Pizzini S, Bisognin A, Parenti S, Montorsi L, Gemelli C, **Zanocco-Marani T**, Zanollevo P, Ferrarini F, Ferrari S, Bortoluzzi S and Grande A *Journal of Carcinogenesis & Mutagenesis*. 2014, 5:154.
22. The Orosomucoid 1 protein is involved in the vitamin D - mediated macrophage deactivation process. Gemelli C, Martello A, Montanari M, **Zanocco Marani T**, Salsi V, Zappavigna V, Parenti S, Vignudelli T, Selmi T, Ferrari S, Grande A. *Exp Cell Res*. 2013 Dec 10;319(20):3201-13.
23. ZFP36 expression impairs glioblastoma cell lines viability and invasiveness by targeting multiple signal transduction pathways. Selmi T, Martello A, Vignudelli T, Ferrari E, Grande A, Gemelli C, Salomoni P, Ferrari S, **Zanocco-Marani T**. *Cell Cycle*. 2012 May 15;11(10):1977-87.
24. TIS11/TTP gene family: it's never too late for tumor suppressors . **Zanocco-Marani T**. *Cell Cycle*. 2010 Dec 15;9(24):4771.
25. ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by interfering with the Stat5b pathway. Vignudelli T, Selmi T, Martello A, Parenti S, Grande A, Gemelli C, **Zanocco-Marani T**, Ferrari S. *Mol Biol Cell*. 2010 Oct 1;21(19): 3340-51.
26. TFE3 transcription factor regulates the expression of MAFB during macrophage differentiation. **Zanocco-Marani T**, Vignudelli T, Parenti S, Gemelli C, Condorelli F, Martello A, Selmi T, Grande A, Ferrari S. *Exp Cell Res*. 2009 Jul 1;315(11):1798-808.
27. The vitamin D3/Hox-A10 pathway supports MafB function during the monocyte differentiation of human CD34+ hemopoietic progenitors. Gemelli C, Orlandi C, **Zanocco Marani T**, Martello A, Vignudelli T, Ferrari F, Montanari M, Parenti S, Testa A, Grande A, Ferrari S. *J Immunol*. 2008 Oct 15;181(8):5660-72.
28. TFE3 expression is closely associated to macrophage terminal differentiation of human hematopoietic myeloid precursors. **Zanocco-Marani T**, Vignudelli T, Gemelli C, Pirondi S, Testa A, Montanari M, Parenti S, Tenedini E, Grande A, Ferrari S. *Exp Cell Res*. 2006 Dec 10;312(20):4079-89.
29. Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia. Tagliafico E, Tenedini E, Manfredini R, Grande A, Ferrari F, Roncaglia E, Bicciato S, Zini R, Salati S, Bianchi E, Gemelli C, Montanari M, Vignudelli T, **Zanocco-Marani T**, Parenti S, Paolucci P, Martinelli G, Piccaluga PP, Baccarani M, Specchia G, Torelli U, Ferrari S. *Leukemia*. 2006 Oct;20(10):1751-8.

30. Virally mediated MafB transduction induces the monocyte commitment of human CD34+ hematopoietic stem/progenitor cells. Gemelli C, Montanari M, Tenedini E, **Zanocco Marani T**, Vignudelli T, Siena M, Zini R, Salati S, Tagliafico E, Manfredini R, Grande A, Ferrari S. *Cell Death Differ.* 2006 Oct;13(10):1686-96.
31. Correlation between differentiation plasticity and mRNA expression profiling of CD34+-derived CD14- and CD14+ human normal myeloid precursors. Montanari M, Gemelli C, Tenedini E, **Zanocco Marani T**, Vignudelli T, Siena M, Zini R, Salati S, Chiossi G, Tagliafico E, Manfredini R, Grande A, Ferrari S. *Cell Death Differ.* 2005 Dec; 12(12):1588-600.
32. The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engraftment. Manfredini R, Zini R, Salati S, Siena M, Tenedini E, Tagliafico E, Montanari M, **Zanocco-Marani T**, Gemelli C, Vignudelli T, Grande A, Fogli M, Rossi L, Fagioli ME, Catani L, Lemoli RM, Ferrari S. *Stem Cells.* 2005 Apr;23(4):496-506.
33. Development of an IL-6 antagonist peptide that induces apoptosis in 7TD1 cells. Manfredini R, Tenedini E, Siena M, Tagliafico E, Montanari M, Grande A, **Zanocco- Marani T**, Poligani C, Zini R, Gemelli C, Bergamaschi A, Vignudelli T, De Rienzo F, De Benedetti PG, Menziani MC, Ferrari S. *Peptides.* 2003 Aug;24(8):1207-20.
34. Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes. Cortesi L, Turchetti D, Bertoni C, **Zanocco-Marani T**, Vinceti M, Silvestri C, Federico M, Silingardi V, Ferrari S. *Eur J Hum Genet.* 2003 Mar;11(3): 210-4.
35. Requirement of the coiled-coil domains of p92(c-Fes) for nuclear localization in myeloid cells upon induction of differentiation. Tagliafico E, Siena M, **Zanocco-Marani T**, Manfredini R, Tenedini E, Montanari M, Grande A, Ferrari S. *Oncogene.* 2003 Mar 20;22(11):1712-23.
36. Gene expression profile of Vitamin D3 treated HL60 cells shows an incomplete molecular phenotypic conversion to monocytes. Tagliafico E, Tenedini E, Bergamaschi A, Manfredini R, Percudani R, Siena M, **Zanocco-Marani T**, Grande A, Montanari M, Gemelli C, Torelli U, Ferrari S. *Cell Death Differ.* 2002 Nov;9(11):1185-95.
37. Physiological levels of 1alpha, 25 dihydroxyvitamin D3 induce the monocytic commitment of CD34+ hematopoietic progenitors. Grande A, Montanari M, Tagliafico E, Manfredini R, **Zanocco Marani T**, Siena M, Tenedini E, Gallinelli A, Ferrari S. *J Leukoc Biol.* 2002 Apr;71(4):641-51.
38. Efficient in vitro and in vivo gene regulation of a retrovirally delivered pro-apoptotic actor under the control of the Drosophila HSP70 promoter. Romano G, Reiss K, Tu X, Peruzzi F, Belletti B, Wang JY, **Zanocco-Marani T**, Baserga R. *Gene Ther.* 2001 Apr; 8(8):600-7.
39. A functionally active RARalpha nuclear receptor is expressed in retinoic acid non responsive early myeloblastic cell lines. Grande A, Montanari M, Manfredini R, Tagliafico E, **Zanocco-Marani T**, Trevisan F, Ligabue G, Siena M, Ferrari S, Ferrari S. *Cell Death Differ.* 2001 Jan;8(1):70-82.
40. Insulin receptor substrate-1, p70S6K, and cell size in transformation and differentiation of hemopoietic cells. Valentinis B, Navarro M, **Zanocco-Marani T**, Edmonds P, McCormick J, Morrione A, Sacchi A, Romano G, Reiss K, Baserga R. *J Biol Chem.* 2000 Aug 18;275(33):25451-9.
41. Biological activities and signaling pathways of the granulins/epithelins precursor. **Zanocco-Marani T**, Bateman A, Romano G, Valentinis B, He ZH, Baserga R. *Cancer Res.* 1999 Oct 15;59(20):5331-40.
42. Dissociation between resistance to apoptosis and the transformed phenotype in IGF-I receptor signaling. Romano G, Prisco M, **Zanocco-Marani T**, Peruzzi F, Valentinis B, Baserga R. *J Cell Biochem.* 1999 Feb 1;72(2):294-310.
43. The granulins/epithelins precursor abrogates the requirement for the insulin-like growth factor 1 receptor for growth in vitro. Xu SQ, Tang D, Chamberlain S, Pronk G, Masiarz FR, Kaur S, Prisco M, **Zanocco-Marani T**, Baserga R. *J Biol Chem.* 1998 Aug 7;273(32):20078-83.

Modena, July, 20th, 2026

W. L. M.